WO2001003325A3 - Verwendung von kreatin und/oder kreatin-derivaten zur behandlung von befindlichkeitsstörungen bei frauen - Google Patents

Verwendung von kreatin und/oder kreatin-derivaten zur behandlung von befindlichkeitsstörungen bei frauen Download PDF

Info

Publication number
WO2001003325A3
WO2001003325A3 PCT/EP2000/006084 EP0006084W WO0103325A3 WO 2001003325 A3 WO2001003325 A3 WO 2001003325A3 EP 0006084 W EP0006084 W EP 0006084W WO 0103325 A3 WO0103325 A3 WO 0103325A3
Authority
WO
WIPO (PCT)
Prior art keywords
creatine
derivatives
women
ill
health
Prior art date
Application number
PCT/EP2000/006084
Other languages
English (en)
French (fr)
Other versions
WO2001003325A2 (de
Inventor
Ivo Pischel
Helen Louise Holland
Brigitta Schwartz
Andrea Huber
Ralf Jaeger
Original Assignee
Sueddeutsche Kalkstickstoff
Ivo Pischel
Helen Louise Holland
Brigitta Schwartz
Andrea Huber
Ralf Jaeger
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from DE19929995A external-priority patent/DE19929995B4/de
Application filed by Sueddeutsche Kalkstickstoff, Ivo Pischel, Helen Louise Holland, Brigitta Schwartz, Andrea Huber, Ralf Jaeger filed Critical Sueddeutsche Kalkstickstoff
Priority to AU61532/00A priority Critical patent/AU6153200A/en
Publication of WO2001003325A2 publication Critical patent/WO2001003325A2/de
Publication of WO2001003325A3 publication Critical patent/WO2001003325A3/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/223—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of alpha-aminoacids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/341—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide not condensed with another ring, e.g. ranitidine, furosemide, bufetolol, muscarine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Reproductive Health (AREA)
  • Diabetes (AREA)
  • Emergency Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Beschrieben wird die Verwendung von Kreatin und/oder Kreatin-Derivaten zur Behandlung von Befindlichkeitsstörungen bei Frauen wie PMS oder Dysmenorrhoe, wobei insbesondere das Kreatin-monohydrat, -pyruvate, -ascorbate und -α-Ketoglutarate als Kreatin-Derivate in bevorzugten Tagesdosen von 0,1 bis 20 g/d für die Prophylaxe oder in Form eines Therapeutikums eingesetzt werden. Vorgesehen ist ebenfalls, das Kreatin oder dessen Derivate als Mischungen mit einem Pyruvat, Ascorbat oder α-Ketoglutarat zu verwenden, wobei das Kreatin oder dessen entsprechende Derivate nicht auf eine bestimmte Verabreichungsform beschränkt sind, was sie zusätzlich für viele Symptome der weiblichen Befindlichkeitsstörungen geeignet macht.
PCT/EP2000/006084 1999-06-30 2000-06-29 Verwendung von kreatin und/oder kreatin-derivaten zur behandlung von befindlichkeitsstörungen bei frauen WO2001003325A2 (de)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU61532/00A AU6153200A (en) 1999-06-30 2000-06-29 Use of creatine and/or creatine derivatives for treating feelings of ill-health in women

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
DE19929995A DE19929995B4 (de) 1999-06-30 1999-06-30 Verwendung von Kreatin und/oder Kreatin-Derivaten zur Behandlung von Befindlichkeitsstörungen bei Frauen
DE19929995.1 1999-06-30
US09/491,662 2000-01-27
US09/491,662 US6503951B2 (en) 1999-06-30 2000-01-27 Use of creatine and/or creatine derivatives for treating typical disorders in women

Publications (2)

Publication Number Publication Date
WO2001003325A2 WO2001003325A2 (de) 2001-01-11
WO2001003325A3 true WO2001003325A3 (de) 2001-08-02

Family

ID=26053993

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2000/006084 WO2001003325A2 (de) 1999-06-30 2000-06-29 Verwendung von kreatin und/oder kreatin-derivaten zur behandlung von befindlichkeitsstörungen bei frauen

Country Status (2)

Country Link
AU (1) AU6153200A (de)
WO (1) WO2001003325A2 (de)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10003835A1 (de) * 2000-01-28 2001-08-16 Sueddeutsche Kalkstickstoff Formulierungen bei Dehydratationszuständen
DE10032964B4 (de) * 2000-07-06 2017-10-12 Beiersdorf Ag Verwendung von Kreatin in kosmetischen oder dermatologischen Zubereitungen
US20030212136A1 (en) 2001-09-14 2003-11-13 Vennerstrom Jonathan L. Creatine ester pronutrient compounds and formulations
EP1688139A1 (de) * 2000-09-14 2006-08-09 Board of Regents of the University of Nebraska Kreatinester-Verbindungen und -Formulierungen
US9833427B2 (en) 2000-09-14 2017-12-05 Board Of Regents Of The University Of Nebraska Creatine ester anti-inflammatory compounds and formulations
BR0211814A (pt) * 2001-08-09 2004-09-08 Degussa Food Ingredients Gmbh Formulação contendo (liso-)fosfatidilserina para a prevenção e tratamento de estados de tensão em animais de sangue quente

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994017794A1 (en) * 1993-02-03 1994-08-18 Steven Andrew Jennings Blends of glycine derivatives and sugars
WO1996014063A1 (en) * 1994-11-08 1996-05-17 Avicena Group, Inc. Use of creatine or creatine analogs for the treatment of diseases of the nervous system
US5627172A (en) * 1994-03-04 1997-05-06 Natural Supplement Association, Incorporated Method for reduction of serum blood lipids or lipoprotein fraction
WO1998028263A1 (de) * 1996-12-20 1998-07-02 Skw Trostberg Aktiengesellschaft Kreatin-pyruvate und verfahren zu deren herstellung
WO1999000122A1 (de) * 1997-06-25 1999-01-07 Ipr-Institute For Pharmaceutical Research Ag Verfahren zur reduktion des körpergewichtes
US6080788A (en) * 1997-03-27 2000-06-27 Sole; Michael J. Composition for improvement of cellular nutrition and mitochondrial energetics

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994017794A1 (en) * 1993-02-03 1994-08-18 Steven Andrew Jennings Blends of glycine derivatives and sugars
US5627172A (en) * 1994-03-04 1997-05-06 Natural Supplement Association, Incorporated Method for reduction of serum blood lipids or lipoprotein fraction
WO1996014063A1 (en) * 1994-11-08 1996-05-17 Avicena Group, Inc. Use of creatine or creatine analogs for the treatment of diseases of the nervous system
WO1998028263A1 (de) * 1996-12-20 1998-07-02 Skw Trostberg Aktiengesellschaft Kreatin-pyruvate und verfahren zu deren herstellung
US6080788A (en) * 1997-03-27 2000-06-27 Sole; Michael J. Composition for improvement of cellular nutrition and mitochondrial energetics
WO1999000122A1 (de) * 1997-06-25 1999-01-07 Ipr-Institute For Pharmaceutical Research Ag Verfahren zur reduktion des körpergewichtes

Also Published As

Publication number Publication date
AU6153200A (en) 2001-01-22
WO2001003325A2 (de) 2001-01-11

Similar Documents

Publication Publication Date Title
AU2548899A (en) Composition comprising theanine
WO2001066564A3 (en) Gamma-secretase inhibitors
CA2304770A1 (en) A use of steroidal saponins for the prophylaxis or treatment of dementia, and novel steroidal saponin compounds
WO2001090091A8 (en) Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1
GB2288732B (en) Pharmaceutical compositions
YU59600A (sh) Supstituisane indolalkanoidske kiseline
CA2029420A1 (en) Pharmaceutical compositions and methods for inhibition of maillard's reaction
PL361341A1 (en) Novel pharmaceutical composition
CA2348086A1 (en) Controlled-release pharmaceutical formulations
TW225532B (de)
AU5669198A (en) Cyclosporin derivative, its preparation and pharmaceutical compositions containing same
GB2320431B (en) Compositions for the treatment of chronic wounds
WO2000021910A3 (en) 1,2-disubstituted cyclopropanes
AUPR626101A0 (en) A composition and uses therefor
WO2001003325A3 (de) Verwendung von kreatin und/oder kreatin-derivaten zur behandlung von befindlichkeitsstörungen bei frauen
WO1996022305A3 (en) Modified peptides
RS8504A (en) Novel cyclohexil sulphones
CA2200126A1 (en) Treatment and prophylaxis of pancreatitis
AU3866997A (en) Preventive or remedy for alzheimer's disease
WO1999061010A3 (en) Treatment of infertility with cam-increasing compounds alone or in combination with at least one meiosis-stimulating compound
ZA941464B (en) Use of pregnane derivative
WO1999011256A8 (fr) L-threonate ferreux, composition pharmaceutique le contenant et son utilisation pour reduire et traiter l'anemie chez l'homme
ZA922504B (en) Novel 2-spirocyclopropyl 4-acylcephems and processes for the preparation thereof
GR3018711T3 (en) (p-Carbonylaminophenyl)-sulphonyl-nitromethane derivatives
WO2000000188A3 (en) Synthetically prepared hydroxy citric acid composition for the treatment and/or prophylaxis of overweight and use thereof

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP